血清 miR-124 作为骨肉瘤诊断和预后生物标志物的鉴定。

Identification of serum miR-124 as a biomarker for diagnosis and prognosis in osteosarcoma.

机构信息

Department of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

Department of Orthopedics, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

出版信息

Cancer Biomark. 2018 Feb 6;21(2):449-454. doi: 10.3233/CBM-170672.

DOI:10.3233/CBM-170672

PMID:29125481

Abstract

BACKGROUND

It has been demonstrated that microRNAs (miRNAs) play an important role in the carcinogenesis of osteosarcoma.

OBJECTIVE

The aim of the present study was to determine the diagnostic and prognostic value of serum miR-124 in osteosarcoma.

METHODS

The serum miR-124 expression levels in 114 osteosarcoma patients, 40 periostitis patients and 50 normal controls were detected using real-time quantitative polymerase chain reaction (RT-qPCR).

RESULTS

The level of serum miR-124 was remarkably decreased in osteosarcoma patients when compared to periostitis patients and healthy controls (both p< 0.05). The serum miR-124 levels in osteosarcoma patients were significantly elevated after receiving surgical treatment (p< 0.01). Furthermore, the area under the receiver-operating characteristic (ROC) curve (AUC) for serum miR-124 was 0.846, combining with 79.8% sensitivity and 86.00% specificity. A significant correlation was detected between serum miR-124 expression and distant metastasis (p= 0.0256) as well as clinical stage (p= 0.0006). Similarly, serum miR-124 levels in patients with advanced clinical stage or positive distant metastasis were significantly decreased. Moreover, the Kaplan-Meier method with log-rank test showed that osteosarcoma patients with lower serum miR-124 levels had unfavorable 5 year overall survival and disease free survival rates. Finally, multivariate analysis revealed that serum miR-124 was an independent prognostic indicator for osteosarcoma.

CONCLUSIONS

These findings suggested that serum miR-124 might be a promising biomarker with diagnostic and prognostic value for osteosarcoma.

摘要

背景

已经证明 microRNAs（miRNAs）在骨肉瘤的发生发展中起着重要作用。

目的

本研究旨在确定血清 miR-124 在骨肉瘤中的诊断和预后价值。

方法

采用实时定量聚合酶链反应（RT-qPCR）检测 114 例骨肉瘤患者、40 例骨膜炎患者和 50 例正常对照者血清 miR-124 的表达水平。

结果

与骨膜炎患者和健康对照组相比，骨肉瘤患者血清 miR-124 水平显著降低（均 p<0.05）。骨肉瘤患者接受手术治疗后，血清 miR-124 水平显著升高（p<0.01）。此外，血清 miR-124 的受试者工作特征（ROC）曲线下面积（AUC）为 0.846，结合 79.8%的敏感性和 86.00%的特异性。血清 miR-124 表达与远处转移（p=0.0256）和临床分期（p=0.0006）显著相关。同样，临床分期较高或发生远处转移的患者血清 miR-124 水平显著降低。此外，Kaplan-Meier 法和对数秩检验显示，血清 miR-124 水平较低的骨肉瘤患者 5 年总生存率和无病生存率较差。最后，多因素分析显示，血清 miR-124 是骨肉瘤的独立预后指标。